First human test of new Cancer-Fighting immune cells begins
NCT ID NCT06088472
Summary
This early-stage study is testing the safety of a personalized immune cell therapy called TIL injection (GT101) for adults with metastatic or recurrent solid tumors. Researchers will collect a patient's own tumor-fighting immune cells, grow them in a lab, and reinfuse them back into the body. The main goal is to see what side effects occur and how severe they are, while also checking if the treatment shows any signs of shrinking tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Affiliated Hospital of Xuzhou Medical University
RECRUITINGXuzhou, Jiangsu, 221000, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.